tradingkey.logo

ImmuCell Corp

ICCC
5.970USD
-0.170-2.77%
收盤 12/19, 16:00美東報價延遲15分鐘
54.00M總市值
21.77本益比TTM

ImmuCell Corp

5.970
-0.170-2.77%

關於 ImmuCell Corp 公司

ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).

ImmuCell Corp簡介

公司代碼ICCC
公司名稱ImmuCell Corp
上市日期May 01, 1987
CEOte Boekhorst (Olivier)
員工數量69
證券類型Ordinary Share
年結日May 01
公司地址56 Evergreen Drive
城市PORTLAND
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編04103
電話12078782770
網址https://immucell.com/
公司代碼ICCC
上市日期May 01, 1987
CEOte Boekhorst (Olivier)

ImmuCell Corp公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Michael F. Brigham
Mr. Michael F. Brigham
Director
Director
215.75K
--
Dr. David Scott Tomsche, M.D.
Dr. David Scott Tomsche, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
133.43K
+1.24%
Ms. Bobbi Jo Brockmann
Ms. Bobbi Jo Brockmann
Vice President - Sales and Marketing, Director
Vice President - Sales and Marketing, Director
8.52K
--
Mr. Bryan K. Gathagan
Mr. Bryan K. Gathagan
Independent Director
Independent Director
1.00K
--
Mr. Olivier te Boekhorst
Mr. Olivier te Boekhorst
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Paul R. Wainman
Mr. Paul R. Wainman
Independent Director
Independent Director
--
--
Mr. Steven T. Rosgen
Mr. Steven T. Rosgen
Independent Director
Independent Director
--
--
Ms. Gloria J. Basse
Ms. Gloria J. Basse
Independent Director
Independent Director
--
--
Mr. Timothy C. Fiori
Mr. Timothy C. Fiori
Chief Financial Officer, Treasurer, Secretary, Director
Chief Financial Officer, Treasurer, Secretary, Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Michael F. Brigham
Mr. Michael F. Brigham
Director
Director
215.75K
--
Dr. David Scott Tomsche, M.D.
Dr. David Scott Tomsche, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
133.43K
+1.24%
Ms. Bobbi Jo Brockmann
Ms. Bobbi Jo Brockmann
Vice President - Sales and Marketing, Director
Vice President - Sales and Marketing, Director
8.52K
--
Mr. Bryan K. Gathagan
Mr. Bryan K. Gathagan
Independent Director
Independent Director
1.00K
--
Mr. Olivier te Boekhorst
Mr. Olivier te Boekhorst
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Paul R. Wainman
Mr. Paul R. Wainman
Independent Director
Independent Director
--
--

收入明細

單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
First Defense® product line
6.40M
99.28%
Other animal health
46.36K
0.72%
地區USD
名稱
營收
佔比
United States
4.87M
75.63%
Other
1.57M
24.37%
業務
地區
業務USD
名稱
營收
佔比
First Defense® product line
6.40M
99.28%
Other animal health
46.36K
0.72%

股東統計

更新時間: 12月4日 週四
更新時間: 12月4日 週四
持股股東
股東類型
持股股東
持股股東
佔比
Knudsen (Ejnar A III)
9.21%
Pessin (Norman H)
7.12%
Rothschild (Jonathan E)
5.68%
SRK Capital, LLC
5.55%
Pessin (Sandra F)
4.44%
其他
68.00%
持股股東
持股股東
佔比
Knudsen (Ejnar A III)
9.21%
Pessin (Norman H)
7.12%
Rothschild (Jonathan E)
5.68%
SRK Capital, LLC
5.55%
Pessin (Sandra F)
4.44%
其他
68.00%
股東類型
持股股東
佔比
Individual Investor
32.25%
Investment Advisor
14.31%
Investment Advisor/Hedge Fund
3.60%
Hedge Fund
1.98%
Research Firm
0.02%
其他
47.84%

機構持股

更新時間: 10月5日 週日
更新時間: 10月5日 週日
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
46
1.81M
20.03%
-84.61K
2025Q2
56
4.25M
46.97%
-88.13K
2025Q1
59
4.81M
59.23%
+487.91K
2024Q4
58
4.30M
48.30%
+425.64K
2024Q3
56
4.25M
49.53%
+427.28K
2024Q2
57
3.67M
43.77%
+363.56K
2024Q1
55
3.19M
41.22%
-172.12K
2023Q4
55
3.22M
41.55%
-93.50K
2023Q3
57
3.23M
41.67%
-83.77K
2023Q2
56
3.25M
41.94%
-58.60K
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
Knudsen (Ejnar A III)
463.62K
5.13%
--
--
Apr 14, 2025
Pessin (Norman H)
644.02K
7.12%
--
--
Apr 14, 2025
Rothschild (Jonathan E)
514.00K
5.68%
--
--
Apr 14, 2025
SRK Capital, LLC
502.26K
5.55%
--
--
Apr 14, 2025
Pessin (Sandra F)
401.82K
4.44%
--
--
Apr 14, 2025
The Vanguard Group, Inc.
308.70K
3.41%
+83.11K
+36.84%
Jun 30, 2025
Brigham (Michael F)
215.75K
2.39%
--
--
Apr 14, 2025
Renaissance Technologies LLC
159.99K
1.77%
+26.00K
+19.40%
Jun 30, 2025
Pessin (Brian L)
136.88K
1.51%
--
--
Apr 14, 2025
Tomsche (David Scott)
131.80K
1.46%
+24.37K
+22.69%
Apr 14, 2025
查看更多

持股ETF

更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
iShares Micro-Cap ETF
0.01%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
佔比0.01%
DFA Dimensional US Sustainability Core 1 ETF
佔比0%
Dimensional US Core Equity 1 ETF
佔比0%

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據

常見問題

ImmuCell Corp的前五大股東是誰?

ImmuCell Corp的前五大股東如下:
Knudsen (Ejnar A III)
持有股份:463.62K
佔總股份比例:5.13%。
Pessin (Norman H)
持有股份:644.02K
佔總股份比例:7.12%。
Rothschild (Jonathan E)
持有股份:514.00K
佔總股份比例:5.68%。
SRK Capital, LLC
持有股份:502.26K
佔總股份比例:5.55%。
Pessin (Sandra F)
持有股份:401.82K
佔總股份比例:4.44%。

ImmuCell Corp的前三大股東類型是什麼?

ImmuCell Corp 的前三大股東類型分別是:
Knudsen (Ejnar A III)
Pessin (Norman H)
Rothschild (Jonathan E)

有多少機構持有ImmuCell Corp(ICCC)的股份?

截至2025Q3,共有46家機構持有ImmuCell Corp的股份,合計持有的股份價值約為1.81M,占公司總股份的20.03% 。與2025Q2相比,機構持股有所增加,增幅為-26.94%。

哪個業務部門對ImmuCell Corp的收入貢獻最大?

在FY2025Q2,First Defense® product line業務部門對ImmuCell Corp的收入貢獻最大,創收6.40M,占總收入的99.28% 。
KeyAI